Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy

BACKGROUND: Aberrant activation NF-kappaB has been proposed as a mechanism of drug resistance in pancreatic cancer. Recently, inhibition of glycogen synthase kinase-3 has been shown to exert anti-tumor effects on pancreatic cancer cells by suppressing NF-kappaB. Consequently, we investigated whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamaghani, Shadi, Patel, Satish, Hedley, David W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685435/
https://www.ncbi.nlm.nih.gov/pubmed/19405981
http://dx.doi.org/10.1186/1471-2407-9-132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685435/
https://www.ncbi.nlm.nih.gov/pubmed/19405981
http://dx.doi.org/10.1186/1471-2407-9-132

Ejemplares similares